What are the reference range guidelines for serum dihydrotestosterone (DHT) levels in adult women?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Reference Range Guidelines for Dihydrotestosterone (DHT) in Adult Women

The established reference range for serum dihydrotestosterone in adult premenopausal women is 0.09-0.91 nmol/L (approximately 3-26 ng/dL), based on validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodology 1.

Validated Reference Intervals

The most reliable DHT reference ranges for women come from studies using LC-MS/MS, which is the gold standard for androgen measurement:

  • Premenopausal women: 0.09-0.91 nmol/L (mean ± 2 SD) 1
  • Alternative reported range: 9-18 ng/100 mL (18 ± 8 ng/100 mL mean ± 1 SD) 2

These values are substantially lower than those obtained by older radioimmunoassay (RIA) methods, which lack specificity and produce falsely elevated results 1.

Critical Measurement Considerations

Assay Method Matters Critically

You must verify that your laboratory uses LC-MS/MS or gas chromatography-mass spectrometry (GC-MS) for DHT measurement 3, 4. The automated immunoassays available in most hospital laboratories are not suitable for accurately measuring androgens in women due to:

  • Poor sensitivity at female concentration ranges
  • Cross-reactivity with other steroids
  • Systematic differences between assay platforms 4

Clinical Context for DHT Measurement

DHT measurement is not routinely recommended for evaluating hyperandrogenism in women 4. Here's why:

  • Testosterone is the key androgen to measure, not DHT 4
  • Plasma DHT levels do not correlate well with tissue-level 5α-reductase activity in hair follicles and sebaceous glands 5
  • DHT measurement provides limited additional diagnostic value beyond testosterone and free testosterone 4

When DHT Levels May Be Relevant

DHT becomes clinically relevant in specific scenarios:

  1. Testosterone replacement monitoring in men using scrotal patches - where 5α-reductase activity in scrotal skin causes markedly elevated DHT levels 6

  2. Evaluating 5α-reductase inhibitor therapy (finasteride) - where DHT levels should decrease while testosterone may increase 5

  3. Research contexts examining androgen metabolism, particularly the testosterone-to-DHT ratio in PCOS patients with metabolic dysfunction 7

Practical Algorithm for Androgen Assessment in Women

Instead of measuring DHT, follow this evidence-based approach for evaluating hyperandrogenism:

Step 1: Measure testosterone properly

  • Use LC-MS/MS methodology if available
  • Obtain early morning, follicular phase sample (days 3-6 of cycle)
  • Measure both total and free testosterone 4

Step 2: Assess SHBG

  • SHBG determines the bioavailable fraction of testosterone
  • Low SHBG (common in obesity, insulin resistance) increases free testosterone even when total testosterone is normal 4

Step 3: Consider additional androgens only if indicated

  • DHEAS >600 μg/dL (16,000 nmol/L): suggests adrenal tumor 3
  • Testosterone >2.5 nmol/L: warrants DHEAS measurement 8
  • 17-hydroxyprogesterone: only in high-risk ethnic groups for non-classic congenital adrenal hyperplasia 4

Common Pitfalls to Avoid

  1. Using immunoassays for female androgen measurement - these produce unreliable results at female concentration ranges 4, 1

  2. Measuring DHT routinely for hirsutism evaluation - it adds no diagnostic value and is not recommended by guidelines 5, 4

  3. Ignoring assay-specific reference ranges - normal ranges vary widely between laboratories and methods 4

  4. Failing to account for SHBG - total testosterone may be normal while free testosterone is elevated 4

Special Population Considerations

For transgender women on gender-affirming hormone therapy, DHT reference ranges should align with the affirmed gender after ≥12 months of treatment, though specific DHT guidelines for this population are not well-established 9.

The testosterone-to-DHT ratio (rather than absolute DHT levels) may have emerging utility in identifying PCOS patients with insulin resistance and metabolic dysfunction, with higher ratios correlating with worse metabolic profiles 7.

References

3
Guideline

recommendations for investigation of hyperandrogenism.

Annales d'endocrinologie, 2010

5
Guideline

american association of clinical endocrinologists medical guidelines for the clinical practice for the diagnosis and treatment of hyperandrogenic disorders.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2001

6
Guideline

american association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2003

8
Guideline

reproductive dysfunction in women with epilepsy: recommendations for evaluation and management.

Journal of Neurology, Neurosurgery and Psychiatry, 2002

Related Questions

Which testosterone laboratory test should be ordered for women?
In a 31-year-old woman with polycystic ovary syndrome and elevated total testosterone (85 ng/dL) and free testosterone (4.5 pg/mL) presenting with chronic diffuse hair loss without scalp lesions, what further evaluation is recommended?
In a 43-year-old woman with progesterone <0.5 ng/mL, estradiol <30 pg/mL, luteinizing hormone ≈12 IU/L, follicle‑stimulating hormone ≈9 IU/L, total testosterone 23 ng/dL, free testosterone 2.9 pg/mL, and sex hormone‑binding globulin 82 nmol/L, what is the most likely diagnosis and what is the appropriate first‑line management?
In a 53-year-old woman whose serum testosterone rose from 47 ng/dL to 390 ng/dL over two months, what is the appropriate evaluation and management?
A 28-year-old woman with a two-year history of irregular menses, polycystic-appearing ovaries on ultrasound, and elevated serum testosterone—does she meet criteria for polycystic ovary syndrome (PCOS) and what management recommendations should be pursued?
What is the appropriate DVT prophylaxis for a patient with decompensated cirrhosis, markedly elevated INR, and thrombocytopenia?
Should a urinalysis be obtained for a patient taking empagliflozin (Jardiance) who has vaginal irritation and urinary symptoms?
What are appropriate pharmacologic and non‑pharmacologic treatment options for a patient with anxiety who declines a selective serotonin reuptake inhibitor (SSRI)?
How should a 1 cm concentric left ventricular hypertrophy be evaluated and managed?
Can oral micronized progesterone be used nightly as monotherapy for perimenopausal symptoms in a typical 45‑55‑year‑old woman without contraindications?
Can tranexamic acid (Transamine) be administered to a 3‑year‑old child with hematemesis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.